氟米龙0.1%作为倒睫手术辅助治疗:随机临床试验
在埃塞俄比亚农村医院接受上睑倒睫手术的患者中,氟米龙0.1%滴眼液不同频次与安慰剂相比,1年内眼压升高≥30 mmHg仅1例、过敏反应仅1例,均停药后缓解,无白内障或其他剂量限制性毒性。结论提示氟米龙可能安全有效,每日2次用4周为最有前景的剂量,尚需完整临床试验确认。
要点
- 氟米龙0.1%每日2次用4周可能是减少倒睫术后复发的 promising 剂量。
- 76只每日4次用药眼中仅1例眼压≥30 mmHg、1例过敏,停药后均缓解。
核心结论
- 氟米龙0.1%可能安全且有效减少倒睫术后复发,每日2次用4周为最有前景剂量。
- 需完整规模临床试验确认后方可用于规划实施。
研究设计与样本
- 随机、安慰剂对照、双盲、平行剂量范围临床试验。
- 在埃塞俄比亚农村医院接受上睑倒睫手术的患者随机接受氟米龙0.1%每日2次4周、每日4次4周、每日4次8周或匹配频次安慰剂,按3:1比例分配至相应组,随机化按倒睫严重程度(1-4根 vs ≥5根睫毛触及眼球)分层,随访1年。
主要发现
- 指定组随机人数分别为39:13:39:13:38:13,8周氟米龙组1例退出;154例中148例(96.1%)完成1年随访。
- 76只每日4次氟米龙眼中,1只出现眼压升高≥30 mmHg(升至37 mmHg),1只发生归因于研究药物的过敏反应,均停药后缓解无后遗症。
- 未发生白内障或其他剂量限制性毒性事件。
关键数值与推荐
- 安全性结局包括眼压升高、白内障和其他剂量限制性毒性,随访1年。
- 术后倒睫复发率在1年内评估。
临床怎么用
- 氟米龙0.1%每日2次用4周可作为倒睫术后辅助治疗的候选方案,但需完整临床试验确认后再用于规划实施。
局限性
- 结果需完整规模临床试验确认后方可用于规划实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the hypothesis that fluorometholone 0.1% eye drops are safe and effective as adjunctive therapy for trachomatous trichiasis (TT) surgery; determining the most promising dose. DESIGN: Randomized, placebo-controlled, double-masked parallel dose-ranging clinical trial. METHODS: Patients undergoing upper lid TT surgery at a rural Ethiopian hospital were randomized to fluorometholone 0.1% twice daily for 4 weeks, 4 times daily for 4 weeks, 4 times daily for 8 weeks, or matching frequency placebo in a 3:1:3:1:3:1 ratio for 1 eye. Randomization was stratified by TT severity (1-4 vs ≥5 lashes touching the globe). Safety outcomes (intraocular pressure [IOP] elevation, cataract, and other dose-limiting toxicities) and postoperative TT incidence were assessed over 1 year. RESULTS: Subjects randomized were 39:13:39:13:38:13 in the respective groups, and 1 subject in the 8-weeks fluorometholone group was withdrawn. Of 154 subjects, 148 (96.1%) completed 1 year's follow-up. Among 76 eyes receiving fluorometholone 4 times daily, 1 developed IOP elevation ≥ 30 mm Hg (to 37 mm Hg) and 1 had an allergic reaction attributed to the study drug; each resolved upon drug cessation without sequelae. No cataract or other dose-limiting toxicity events occurred. Postoperative TT within 1 year occurred in 29.3% of placebo eyes vs 17.7%, 19.6%, and 23.2% among the respective fluorometholone groups (P = .29 comparing placebo vs all active treatments combined). CONCLUSIONS: The results suggest fluorometholone 0.1% is likely to be safe and efficacious to reduce postoperative TT following TT surgery, and 1 drop twice daily for 4 weeks is the most promising dose. Confirmation in a full-scale clinical trial is needed before programmatic implementation.
引用
- Kempen JH, Tekle-Haimanot R, Hunduma L, et al. Fluorometholone 0.1% as Ancillary Therapy for Trachomatous Trichiasis Surgery: Randomized Clinical Trial. Am J Ophthalmol. 2018. PMID: 30267699. doi:10.1016/j.ajo.2018.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。